1.Success in Pain Management by Switch from Gabapentin to Pregabalin: A Case of Lung Cancer
Hiroaki SHIBAHARA ; Eri IMAI ; Natsuko UEMATSU ; Sanae KINOSHITA ; Kaori MANO ; Ayako YAMAMOTO ; Masahiro AOYAMA ; Daisaku NISHIMURA
Journal of the Japanese Association of Rural Medicine 2011;60(2):104-108
The patient was a woman in her 80s, who was referred to the palliative care team in our hospital for pain due to bone metastases from lung cancer. Although gabapentin and ifenprodil tartrate were administrated in addition to opioids and loxoprofen sodium, and the dose of opioids was increased, pain was not relieved remarkably. A switch from gabapentin to pregabalin brought remarkable pain relief. Before the internal use of pregabalin, the patient was often seen lyiing in bed because of pain. However, by pregabalin, she began to walk, pushing her wheelchair and smile often. Her ability to perform the basic activities of daily living was improved. The switch from gabapentin to pregabalin was one effective option when an analgesic adjuvant for cancer pain was chosen.
2.Mirtazapine provided remarkable relief for refractory nausea and vomiting by sunitinib and oxycodone in a patient with renal cancer
Hiroaki Shibahara ; Yumiko Tokura ; Tetsuya Isero ; Toshiki Etani ; Yousuke Ikegami ; Hiroyuki Kamiya ; Yoshihiro Hashimoto ; Yutaka Iwase ; Natsuko Uematsu ; Eri Imai ; Daisaku Nishimura
Palliative Care Research 2012;7(1):514-517
Introduction: Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) and the previous reports show that may reduce nausea by inhibition of the serotonin 5-HT3receptor. Case report: A 38-year-old woman with advanced renal cancer with distant metastases was administered by sunitinib and oxycodone. Refractory nausea and vomiting developed during the course and mirtazapine at a daily dose of 1.875 mg was begun. The patient's nausea improved during the next day, and furthermore, by increasing the daily dose to 3.75 mg, vomiting was also improved on the third day. The therapy could be continued without withdrawal of sunitinib and oxycodone due to digestive symptoms. Although somnolence might be induced at a daily dose of 15 mg, the present low-dose mirtazapine could improve digestive symptoms without somnolence. Conclusion: We conclude that low-dose mirtazapine is one effective option for refractory nausea and vomiting during administration of sunitinib and oxycodone.
3.Pigmentation by transdermal fentanyl patch
Hiroaki Shibahara ; Ei Sekoguchi ; Nagayuki Takeshita ; Shingo Suzuki ; Miho Morimoto ; Sachiko Inaguma ; Yoko Mori ; Sumiyo Kudo ; Yumi Ota ; Mika Nishimura ; Natsuko Uematsu ; Eri Imai ; Daisaku Nishimura
Palliative Care Research 2013;8(1):523-528
Introduction: There has been no case report in which hyperpigmentation developed on the skin area where a transdermal fentanyl patch was applied in a patient. Case report: A 43-year-old man with recurrence of postoperative rectal cancer was treated by cetuximab plus irinotecan and panitumumab plus FOLFIRI. For cancer pain, transdermal fentanyl patch (Fentos®) was administered, and radiation from behind was performed. Hyperpigmentation then appeared on the chest and the abdominal skin sites where the patches were applied. The hyperpigmentation nearly disappeared four months after the fentanyl patch was discontinued. Discussion: The cause of the pigmentation was possibly due to post inflammatory hyperpigmentation secondary to contact dermatitis. It was desirable to conduct patch test and skin biopsy for making an accurate diagnosis. Conclusion: We should pay a careful attention to hyperpigmentation of the skin where a transdermal fentanyl patch is applied.
4.A case of autoimmune enteropathy with CTLA4 haploinsufficiency
Haruka MIYAZAKI ; Namiko HOSHI ; Michitaka KOHASHI ; Eri TOKUNAGA ; Yuna KU ; Haruka TAKENAKA ; Makoto OOI ; Nobuyuki YAMAMOTO ; Suguru UEMURA ; Noriyuki NISHIMURA ; Kazumoto IIJIMA ; Keisuke JIMBO ; Tsubasa OKANO ; Akihiro HOSHINO ; Kohsuke IMAI ; Hirokazu KANEGANE ; Ichiro KOBAYASHI ; Yuzo KODAMA
Intestinal Research 2022;20(1):144-149
Autoimmune enteropathy (AIE) is a rare disease, characterized by intractable diarrhea, villous atrophy of the small intestine, and the presence of circulating anti-enterocyte autoantibodies. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, and mutations in FOXP3, which is a master gene of regulatory T cells (Tregs), are major causes of AIE. Recent studies have demonstrated that mutations in other Treg-associated genes, such as CD25 and CTLA4, show an IPEX-like phenotype. We present the case of a 13-year-old girl with CTLA4 haploinsufficiency, suffering from recurrent immune thrombocytopenic purpura and intractable diarrhea. We detected an autoantibody to the AIE-related 75 kDa antigen (AIE-75), a hallmark of the IPEX syndrome, in her serum. She responded well to a medium dose of prednisolone and a controlled dose of 6-mercaptopurine (6-MP), even after the cessation of prednisolone administration. Serum levels of the soluble interleukin-2 receptor and immunoglobulin G (IgG) were useful in monitoring disease activity during 6-MP therapy. In conclusion, autoimmune-mediated mechanisms, similar to the IPEX syndrome, may be involved in the development of enteropathy in CTLA4 haploinsufficiency. Treatment with 6-MP and monitoring of disease activity using serum levels of soluble interleukin-2 receptor and IgG is suggested for such cases.